District Court: Factual Disputes Preclude Application of Safe Harbor to Gene Editing Technology at the Pleading Stage

January 17, 2025

Reading Time : 2 min

The District of Delaware recently denied a motion to dismiss a patent infringement complaint involving gene editing technology that sought relief under the Safe Harbor Provision of the Hatch-Waxman Act. Specifically, the court found the patentee’s complaint sufficiently alleged at least some uses of the claimed technology that, when taken as true, were not solely uses of a “patented invention” that were “reasonably related” to an FDA submission.

The patents in this case claimed gene editing tools known as bi-directional insertion templates (BDITs) and methods of their use. The patentee accused the defendant of using its patented BDITs for the research, identification and optimization of therapeutic candidates. As an example, the complaint alleged that defendant uses the BDITs as a platform technology to collaborate with other entities to develop therapeutic candidates. The defendant moved to dismiss the complaint, arguing that its accused research activities were reasonably related to obtaining FDA approval, and thus immunized by the Safe Harbor provision of the Hatch-Waxman Act. The defendant argued that it developed its BDIT platform before the asserted patents issued, and its current activity was limited to late-stage development of therapies for FDA approval where the BDITs were incorporated into the therapeutic candidate.

In denying the motion, the court found it could not resolve on a motion to dismiss whether the accused uses of the BDITs were solely for uses reasonably related to obtaining FDA approval. The court noted that the Supreme Court construed “patented inventions” as used in the Hatch-Waxman Act to mean instrumentalities that are subject to premarket approval. Here, the patentee alleged that defendant’s BDITs were used as a tool to generate and identify therapeutic candidates, but the BDITs would not themselves be subject to FDA approval. Thus, at least at the pleading stage, patentee’s allegations were sufficient to preclude application of the Safe Harbor. The court further determined that patent owner’s allegations regarding defendant’s collaborations with other entities to develop therapeutics and defendant’s experimentation to identify potential candidates, when taken as true, reflected commercial activity not reasonably related to obtaining FDA approval. And for this additional reason, the allegations were sufficient to survive a motion to dismiss.

Despite this result, the court acknowledged that BDITs present a “tricky fact pattern” because they are tools that have the potential to be incorporated into the final therapeutic candidate. But here again, the court found that it could not distinguish between early stage development and uses that actually do become part of the therapeutic. 

Practice Tip: While the Safe Harbor Provision affords some protection from claims of patent infringement, those protections are not absolute. As this case demonstrates, it is important to distinguish between technology that will be the subject of FDA review and technology that is used as a tool in development. While the former is likely protected under the Safe Harbor, the latter may fall outside its protections.

BlueAllele Corp. v. Intellia Therapeutics, Inc., 1-24-cv-00791, D.I. 35 (D. Del. Dec. 9, 2024)

Share This Insight

Previous Entries

IP Newsflash

March 24, 2025

The Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) final written decision holding that the prior art exception of AIA Section 102(b)(2)(B) does not apply to a prior sale by an inventor when the sale is conducted in private. According to the Federal Circuit, a sale must disclose the relevant aspects of the invention to the public to qualify for the prior art exception of Section 102(b)(2)(B).

...

Read More

IP Newsflash

March 21, 2025

Under the Lanham Act, a plaintiff who prevails on a trademark infringement claim may be entitled to recover the “defendant’s profits” as damages. The Supreme Court in Dewberry Group, Inc. v. Dewberry Engineers Inc. unanimously construed “defendant’s profits” in 35 USC § 1117(a) to mean that only the named defendant’s profits can be awarded, not the profits of other related corporate entities. The Court, however, left open the possibility that other language in § 1117(a) may allow for damages linked to the profits of related entities, if properly raised and supported.

...

Read More

IP Newsflash

March 13, 2025

In a series of rulings on a motion in limine, the District of Delaware recently distinguished between what qualifies as being incorporated by reference and what does not for the purposes of an anticipation defense. In short, a parenthetical citation was held to be insufficient, while three passages discussing a cited reference met the test.

...

Read More

IP Newsflash

March 4, 2025

On February 28, 2025, the USPTO announced that it was rescinding former Director Vidal’s 2022 memorandum on discretionary denials by the Patent Trial and Appeal Board. The 2022 memorandum effectively narrowed the application of discretionary denials in cases with parallel district court litigation by specifying instances where discretionary denial could not be issued. With the withdrawal of the memorandum, individual PTAB panels will regain flexibility in weighing discretionary denials. While the long-term effect of that increased flexibility is not yet known, the immediate effect is likely to be a shift towards the discretionary analysis applied by PTAB panels before the issuance of the memorandum.

...

Read More

IP Newsflash

March 3, 2025

A District of Delaware judge recently granted a defendant’s motion to include a patent prosecution bar in its proposed protective order after determining that litigation counsel’s ability to practice before the Patent Office—without ever having represented the plaintiffs at the Patent Office in the past—weighed heavily in favor of the bar.

...

Read More

IP Newsflash

February 12, 2025

The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to satisfy the written description requirement. In so doing, the Federal Circuit explained that written description and enablement are evaluated based on the subject matter that is claimed, not the products that practice those claims. As a result, the patentee was not required to describe unclaimed, later-discovered features of the accused products despite the broad language in the claims that undisputedly covered the products.

...

Read More

IP Newsflash

January 24, 2025

The District of Delaware recently rejected a patentee’s argument that non-production of an opinion letter from counsel, combined with knowledge of the patent, warranted a finding that defendant induced infringement.

...

Read More

IP Newsflash

January 17, 2025

The District of Delaware recently denied a motion to dismiss a patent infringement complaint involving gene editing technology that sought relief under the Safe Harbor Provision of the Hatch-Waxman Act. Specifically, the court found the patentee’s complaint sufficiently alleged at least some uses of the claimed technology that, when taken as true, were not solely uses of a “patented invention” that were “reasonably related” to an FDA submission.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.